Article | Understanding the BBB
0
In this article, Patrys CEO and MD Dr James Campbell compares historical access to a medieval town to the unique…
Bioshares | September 2020
Patrys was featured in the latest issue of BioShares in an article titled, “Janssen Shows Interest in SLE Antibodies”. Read…
Newsletter | July 2020
Patrys is pleased to share its latest Newsletter, published July 2020. Key highlights: Letter From Our CEO Media and Analyst…
Bioshares | July 2020
Patrys was featured in the latest issue of BioShares in an article titled, “Patrys – Synthetic Lethality to Kill Cancer…
Health Kick Podcast | With Tim Boreham
Health and Biotech expert, Tim Boreham, interviewed Patrys CEO and MD, Dr James Campbell, for the Health Kick Podcast. Listen…
Article | DDR therapeutics
Patrys CEO and MD, Dr James Campbell, has written an article titled “DDR therapeutics and synthetic lethality – a precise…
Article | AstraZeneca
AstraZeneca has published an article titled, “Combatting cancer by exploiting the DNA Damage Response.” Read it here.
Newsletter | June 2019
Patrys is pleased to share its latest Newsletter, published June 2019. Key highlights: Letter from our CEO Progress with PAT-DX1…
Bioshares | October 2018
Patrys was featured in the latest issue of BioShares in an article titled, “Patrys Selects Indications for Unique Cancer Treatment…
Media | Biopharma Deal Makers
Biopharma Deal Makers has published an article titled, “Nuclear-penetrating DNA binding antibodies as cancer therapies.” Read it here.